Takashi DAN

Education and careers:

1980 March:

Master's course completion of the Osaka University of Pharmaceutical Sciences graduate school, department of pharmaceutical research (pharmacology)

1980 April:

Chugai Pharmaceutical Co., Ltd. (- 2007 June)

2007 July:

Genecare Research Institute Co., Ltd, Director of Drug Discovery Dept.(- 2008 May)

2007 August:

Kyoto University, Institute for Frontier Medical Sciences, lecturer              

(- 2008 March) 　　 　

2012 December:

Tohoku University graduate school of medicine, associate professor

Research skills:

He had been mostly engaging in innovative drug discovery research in the department of R&D of Chugai Pharmaceutical Co., Ltd. He has experience of the broad innovative drug discovery research from the target gene search by molecular biology and gene engineering, high throughput screening (HTS), pharmacological studies using a large-sized wild animal (ape) to the clinical pharmacology examinations. He retired through the director of research institute for drug discovery in Chugai Pharmaceutical Co., Ltd.

In Kyoto University's Institute for Frontier Medical Sciences, he was engaged in starting of the HTS system for efficient iPS cell production.

Licensures:

Ph.D. (pharmacology), pharmacist, clinical laboratory technologist

Academic honors:

2002 - 2005   The Japan Health Sciences Foundation, regulatory committee, vice chairman

2005 - 2010   Ministry of Economy, Trade and Industry and NEDO, "technological strategy map" drug discovery task force (head 2006 and 2010)

Publications (English) : 

1. Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T.A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration.Arterioscler Thromb Vasc Biol. 2013; 33:935-42. 
2. Dan T, van Ypersele de Strihou C, Miyata T. Advanced glycation end products (AGEs) inhibitor. In Oxidative Stress in Applied Basic Research and Clinical Practice Studies on Renal Disorders, edited by Miyata T, Eckardt KU, Nangaku M. 2011 
3. Ohtomo S, Izuhara Y, Nangaku M, Dan T, Ito S, van Ypersele de Strihou C, Miyata T. Body weight control by a high-carbohydrate/low-fat diet slows the progression of diabetic kidney damage in an obese, hypertensive, type 2 diabetic  rat model. J Obes. 2010. [Epub ahead of print]
4. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010 (in press)
5. Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology (Carlton). 2009;14(6):581-7.
6. Takizawa S, Dan T, Uesugi T, Nagata E, Takagi S, van Ypersele de Strihou C, Miyata T. A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage. J Cereb Blood Flow Metab. 2009;29(10):1665-72
7. Miyata T. and Dan T. Inhibition of advanced glycation end products (AGEs): An implicit goal in clinical medicine for the treatment of diabetic nephropathy? Diabetes research and clinical practice 2008, 82, Suppl 1:S25-9
8. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, Ito S, Nangaku M, van Ypersele de Strihou C, and Miyata T. A novel sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterio Thromb Vas Biol 2008 28(10):1767-73
9. Ohtomo S, Nangaku M, Izuhara Y, Yamada N, Dan T, Mori T, Ito S, van Ypersele C, Miyata T. The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. Kidney Int 2008, 74(6):768-74